卡瑞利珠单抗联合替吉奥治疗转移性食管癌的临床疗效比较OA

Objective:To observe the efficacy and safety of camrelizumab combined with tegafur/gimeracil/oteracil potassium in the maintenance treatment of metastatic esophageal cancer.Methods:A total of 86 patients with metastatic esophageal cancer admitted to Yichang Central People's Hospital from January 2019 to November 2021 were divided into an observation group(n=42)receiving camrelizumab combined with tegafur/gimeracil/oteracil potassium and a control group(n=44)receiving tegafur/gimeracil/oteracil potassium according to the random number table method.After 2 cycles of treatment,the clinical efficacy and adverse reactions of the two groups were evaluated.Results:Compared with the control group,the disease control rate(88.10％vs 54.55％)and the clinical benefit response rate(80.95％vs 56.82％)were significantly increased,and the median progression free survival(8.50 months vs 5.90 months)and the median overall survival(17.70 months vs 10.70 months)were significantly prolonged(all P＜0.05).There was no significant differfence in the PD-L1 positive and negative between two goups in the 1-year PFS and 1-year OS population.The incidences of grade Ⅰ-Ⅱ myelosuppression(66.67％vs 4.55％),hand-foot syndrome(38.10％vs 2.27％),stomatitis(59.52％vs 11.36％),and anorexia(42.86％vs 15.91％)in the observation group were significantly higher than those in the control group(all P＜0.05).Conclusion:Camrelizumab combined with tegafur/gimeracil/oteracil potassium can effectively improve the treatment effect of patients with metastatic esophageal cancer,but close attention should be paid to the occurrence of adverse reactions.